Key Takeaways WGS posted Q2 adjusted EPS of $0.50 vs. a loss of$0.08 last year; EPS beat estimates by 400%.WGS' revenues rose 45.6% to $102.7M, driven by 69% growth in exome and genome test revenues.Gross margin expanded 813 bps to 69% as WGS delivered its fourth straight profitable quarter.GeneDx Holdings Corp. (WGS) posted second-quarter 2025 adjusted diluted earnings per share (EPS) of 50 cents against a loss of 8 cents per share in the year-ago period. EPS surpassed the bottom-line estimate of 10 cents ...